<DOC>
	<DOCNO>NCT02499146</DOCNO>
	<brief_summary>As part global clinical development program Palbociclib , study plan cancer patient China . An assessment Palbociclib pharmacokinetics Chinese patient , require Chinese Health Authorities , therefore warrant . In addition , safety efficacy also evaluate . The single multiple 125 mg oral dose pharmacokinetics Palbociclib characterize .</brief_summary>
	<brief_title>Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER ( + ) , HER2 ( - ) Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Palbociclib</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>ER ( + ) , HER2 ( ) , postmenopausal adult ( age 1865 year , inclusive ) Chinese woman proven diagnosis adenocarcinoma breast evidence locoregionally recurrent metastatic disease amenable resection radiation therapy curative intent chemotherapy clinically indicate . a. Postmenopausal woman : . Prior bilateral surgical oophorectomy ; ii . Medically confirm postmenopausal status define spontaneous cessation regular menses least 12 consecutive month alternative pathological physiological cause b . Documentation histologically cytologically confirm diagnosis : i. ER ( + ) breast cancer . c. Documentation HER2 ( ) breast cancer . d. Previously untreated systemic anti cancer therapy locoregionally recurrent metastatic ER+ disease . Measurable disease define per RECIST v.1.1 boneonly disease . Tumor lesions previously irradiate subjected locoregional therapy deem measurable disease progression treat site completion therapy clearly document . HER2positive tumor define documentation erbB2 gene amplification FISH ( define HER2/CEP17 ratio â‰¥2 ) chromogenic situ hybridization ( CISH , define manufacturer 's kit instruction ) documentation HER2 overexpression IHC ( define IHC3+ , IHC2+ FISH CISH confirmation ) base local laboratory result Patients advance , symptomatic , visceral spread , risk lifethreatening complication short term ( include patient massive uncontrolled effusion [ pleural , pericardial , peritoneal ] , pulmonary lymphangitis , 50 % liver involvement ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Palbociclib</keyword>
	<keyword>PD-0332991</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>breast cancer patient</keyword>
	<keyword>Chinese</keyword>
</DOC>